Finally, immune checkpoint inhibitors, such as anti‐PD‐L1 or anti‐CTLA4, are antibodies designed to block surface receptor–ligand interactions that suppress the immune response against cancer cells [46]. The gene discussed is CD274; the disease is cancer.